pharmaceutical and diagnostic company Bio - Techne is buying Exosome Diagnostics , which develops technology that screens for diseases with a liquid biopsy using body fluids , for $ 250 m . If the Massachusetts - based Exosome reaches unspecified milestones the price could more than double . Liquid biopsies are a less invasive alternative to surgical treatments and Exosome says its technology offers a demonstration of a tumour ’s real - time function as well as changes over time . It has commercialised treatments of prostate and breast cancers . The deal is expected to close in early August .
Biotechnology and diagnostic company Bio-Techne is buying Exosome Diagnostics, which develops technology that tests for diseases with a liquid biopsy using body fluids, for $250m. If the Massachusetts-based Exosome hits unspecified milestones the price could more than double. Liquid biopsies are a less invasive alternative to surgical treatments and Exosome says its technology offers a picture of a tumour’s real-time activity as well as changes over time. It has commercialised treatments of prostate and lung cancers. The deal is expected to close in early August.